Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Treatment, Multi-center, Randomized, Doubleblind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to severe COPD.


Options:
A: Arm Label: A1 (any SABA and/or SAMA); Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium, Drug: SABA, Drug: SAMA | Arm Label: A2 (glycopyrronium); Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium, Drug: SABA, Drug: LABA, Drug: SAMA | Arm Label: B1 (any LAMA or LABA and mMRC=1); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: Indacaterol maleate and glycopyrronium bromide, Drug: LAMA, Drug: ICS | Arm Label: B2 (glycopyrronium and mMRC=1); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: Indacaterol maleate and glycopyrronium bromide, Drug: LAMA | Arm Label: C1 (any LABA and ICS); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: ICS | Arm Label: C2 (indacaterol/glycopyrronium); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: ICS | Arm Label: D1 (any LAMA or LABA and mMRC>1); Type: EXPERIMENTAL; Interventions: Drug: LAMA | Arm Label: D2 (indacaterol/glycopyrronium and mMRC>1); Type: EXPERIMENTAL; Interventions: Drug: LAMA | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: SABA; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: LABA; Assigned to Arm(s): A2 (glycopyrronium), B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1), C1 (any LABA and ICS), C2 (indacaterol/glycopyrronium) | Intervention Type: DRUG; Name: Indacaterol maleate and glycopyrronium bromide; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1) | Intervention Type: DRUG; Name: LAMA; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1), D1 (any LAMA or LABA and mMRC>1), D2 (indacaterol/glycopyrronium and mMRC>1) | Intervention Type: DRUG; Name: SAMA; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: ICS; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), C1 (any LABA and ICS), C2 (indacaterol/glycopyrronium)
B: Arm Label: BGF (PT010) MDI 320/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/14.4/9.6 μg | Arm Label: BGF (PT010) MDI 160/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 160/14.4/9.6 μg | Arm Label: BFF (PT009) MDI 320/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BFF MDI 320/9.6 μg | Arm Label: GFF (PT003) MDI 14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: GFF MDI 14.4/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 320/14.4/9.6 μg; Assigned to Arm(s): BGF (PT010) MDI 320/14.4/9.6 μg | Intervention Type: DRUG; Name: GFF MDI 14.4/9.6 μg; Assigned to Arm(s): GFF (PT003) MDI 14.4/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 160/14.4/9.6 μg; Assigned to Arm(s): BGF (PT010) MDI 160/14.4/9.6 μg | Intervention Type: DRUG; Name: BFF MDI 320/9.6 μg; Assigned to Arm(s): BFF (PT009) MDI 320/9.6 μg
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium (QVA149), Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol, Drug: Placebo to indacaterol and glycopyrronium (QVA149) | Intervention Type: DRUG; Name: indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): fluticasone/salmeterol
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone/salmeterol, Drug: Placebo to QVA149 | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149

Answer: C